# A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Source: https://onco.cc/trials/nct04873362/  
OnCo record `nct04873362` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Atezolizumab, Trastuzumab emtansine and Trastuzumab in HER2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy is a phase 3 interventional study registered as NCT04873362 by Hoffmann-La Roche, with 1188 participants enrolled, started 2021-05-04 and due to reach its primary completion in 2027-03-31. Interventions recorded: Atezolizumab, Trastuzumab Emtansine, Placebo and Trastuzumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04873362
- Phase: 3
- Setting: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Sponsor: Hoffmann-La Roche
- Enrolled: 1188

## Sources

- ClinicalTrials.gov NCT04873362: https://clinicaltrials.gov/study/NCT04873362

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct04873362.json